{"created":"2021-03-01T06:34:14.821199+00:00","id":26330,"links":{},"metadata":{"_buckets":{"deposit":"f7bb685c-cc0f-4168-8b82-3ed05d30f298"},"_deposit":{"created_by":17,"id":"26330","owners":[17],"pid":{"revision_id":0,"type":"depid","value":"26330"},"status":"published"},"_oai":{"id":"oai:nagoya.repo.nii.ac.jp:00026330","sets":["499:508:509:2109"]},"author_link":["84954","84955","84956","84957","84958","84959"],"item_1615768549627":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_9_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-08","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"409","bibliographicPageStart":"401","bibliographicVolumeNumber":"80","bibliographic_titles":[{"bibliographic_title":"Nagoya Journal of Medical Science","bibliographic_titleLang":"en"}]}]},"item_9_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The standardized uptake value (SUV) is a marker of tumor glucose metabolism, detected using 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and may reflect tumor aggressiveness. The purpose of this study was to evaluate the clinical significance of maximum SUV (SUVmax) of primary esophageal cancer (EC) lesions. A total of 86 patients with EC who underwent pre-treatment FDG-PET and R0-resection were included in our study. The mean patient age was 65 years, and 87% were men. Histologically, cancers included squamous cell carcinomas, adenocarcinomas, and other tumors in 72, 3, and 11 patients, respectively. Preoperative chemotherapy with or without radiotherapy was performed in 4 and 37 patients, respectively. Measured patient outcomes included the correlation between the SUVmax of the primary EC lesion and clinicopathological factors in patients who did not undergo preoperative treatment (n = 45), and the investigation of relapse-free survival (RFS) according to SUVmax and the relationship between SUVmax and recurrence sites in all patients (n=86). The mean SUVmax was 8.9 ± 4.6, and SUVmax values significantly correlated with tumor invasion depth and stage. The 5-year RFS for the enrolled patients was 57%, and the RFS of patients with SUVmax < 7.0 was better than that of patients with SUVmax ≥ 7.0, with a marginal difference (p = 0.0892). Lymph node recurrences were significantly more common in patients with SUVmax ≥ 7.0, compared to patients with SUVmax < 7.0. Therefore, the SUVmax value of the primary EC lesion before preoperative treatment may be predictive of RFS and lymph node recurrence.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.18999/nagjms.80.3.401","subitem_identifier_reg_type":"JaLC"}]},"item_9_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Nagoya University Graduate School of Medicine, School of Medicine","subitem_publisher_language":"en"}]},"item_9_relation_43":{"attribute_name":"関連情報","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/803.html ","subitem_relation_type_select":"URI"}}]},"item_9_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International","subitem_rights_language":"en","subitem_rights_resource":"http://creativecommons.org/licenses/by-nc-nd/4.0/"}]},"item_9_select_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_9_source_id_61":{"attribute_name":"ISSN（Online）","attribute_value_mlt":[{"subitem_source_identifier":"2186-3326","subitem_source_identifier_type":"EISSN"}]},"item_9_source_id_7":{"attribute_name":"ISSN（print）","attribute_value_mlt":[{"subitem_source_identifier":"0027-7622","subitem_source_identifier_type":"PISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Shimizu, Daisuke","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"84954","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yuasa, Norihiro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"84955","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Miyake, Hideo","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"84956","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takeuchi, Eiji","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"84957","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Miyata, Kanji","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"84958","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Itoh, Shigeki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"84959","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-08-31"}],"displaytype":"detail","filename":"12_Shimizu.pdf","filesize":[{"value":"519.0 kB"}],"format":"application/pdf","licensetype":"license_5","mimetype":"application/pdf","url":{"label":"12_Shimizu.pdf","objectType":"fulltext","url":"https://nagoya.repo.nii.ac.jp/record/26330/files/12_Shimizu.pdf"},"version_id":"20e9ed29-fa77-42fa-8e7f-6f1975d9ebf4"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"esophageal cancer","subitem_subject_scheme":"Other"},{"subitem_subject":"PET","subitem_subject_scheme":"Other"},{"subitem_subject":"prognostic factors","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Clinical significance of SUVmax on preoperative 18F-fluorodeoxyglucose positron emission tomography in patients who underwent R0-esophagectomy for esophageal cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Clinical significance of SUVmax on preoperative 18F-fluorodeoxyglucose positron emission tomography in patients who underwent R0-esophagectomy for esophageal cancer","subitem_title_language":"en"}]},"item_type_id":"9","owner":"17","path":["2109"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2018-08-31"},"publish_date":"2018-08-31","publish_status":"0","recid":"26330","relation_version_is_last":true,"title":["Clinical significance of SUVmax on preoperative 18F-fluorodeoxyglucose positron emission tomography in patients who underwent R0-esophagectomy for esophageal cancer"],"weko_creator_id":"17","weko_shared_id":-1},"updated":"2023-11-16T04:20:00.074830+00:00"}